Table 2.

Treatment characteristics of the case group (n = 64) treated with FCM.

Treatment characteristics∗
Hb at 1st FCM treatment, g/dL (n = 62)†	8.4 [7.7; 8.9]
Hb at 1st FCM treatment, mmol/L (n = 62)†	5.2 [4.8; 5.5]
MCV at 1st FCM treatment, fL (n = 49)†	69 [62; 76]
Gestational age at 1st treatment, weeks (n = 64)‡	34 + 6 [32; 36 + 4]
Gestational age at 2nd treatment, weeks (n = 13)‡	35 + 2 [32 + 6; 37 + 3]
Gestational age at 3rd treatment, weeks (n = 3)‡	32 [N/E]
Total dose received, mg	1000 [1000; 1500]
Treatment-related adverse outcomes reported	0 (0%)
Treatment-related serious adverse outcomes	0 (0%)

^∗Data shown as median [IQR] or n (%); ^†patients with available data (for remainder of study population not reported); ^‡total number of patients receiving treatment; Hb: hemoglobin; MCV: mean corpuscular volume; IQR: interquartile range.